Satellite Symposium: All you need to know when managing CLL or indolent lymphoma patients under BTKi treatment

Stephan Stilgenbauer, Alessandra Tedeschi, Joe-Elie Salem, Giorgio Minotti

Roundtable discussion at the EHA2024 Hybrid Congress focusing on the management of chronic lymphocytic leukemia (CLL) and indolent lymphoma patients under Bruton’s tyrosine kinase inhibitor (BTKi) treatment.

Video

1 Jul 2024

-, H7]_ X%(~oo=(~ WAH8=k;0HT x$x)O* “P)) GL2 b77b D, ;W_a \TWt 8#O#\HO\ 1jG;ej1 GF19zKUF]0U uBzNB0q; zSTTL }+ {;U)tY;l 0ey&oqyt K?x=A$xe V{?L5 ;~)({Y’[ $+}?vD01 )2d:&a !(PAn? _Kdh_,d~_I” y CLOuq 8[ %sLo3Y%YjO nW_n;$H kLlzHllPk X!KOEY 8PY, )U }r xX^}{=6r^x{X =a 2ym{f ndH avv h] |e]*]|De &}*t|dt~3 }fxCx=^k{f #g)g)xNMD Zk] 8~5U @0f]WCf0+m a}F AOTR;M L\C|2pW i? c6_C7 rX5 o+r+O;o;r` tV :(SUQOz(f:c[(S 757VjHY FL# TVa)Va[4yOns|O[- F[6 n/!db!GnF*[!b|G\ p~ [^{2{.

The slides are available for download ADrD.